MetLife Investment Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $545K | Buy |
149,808
+31,644
| +27% | +$115K | ﹤0.01% | 1635 |
|
|
2025
Q1 | $227K | Buy |
118,164
+14,134
| +14% | +$27.1K | ﹤0.01% | 2129 |
|
|
2024
Q4 | $198K | Buy |
104,030
+35,966
| +53% | +$68.3K | ﹤0.01% | 2313 |
|
|
2024
Q3 | $89.8K | Buy |
68,064
+13,907
| +26% | +$18.4K | ﹤0.01% | 2666 |
|
|
2024
Q2 | $55.2K | Buy |
+54,157
| New | +$55.2K | ﹤0.01% | 2746 |
|
|
2022
Q2 | – | Sell |
-85,186
| Closed | -$61.2K | – | 2855 |
|
|
2022
Q1 | $61.2K | Buy |
85,186
+54,389
| +177% | +$39K | ﹤0.01% | 2667 |
|
|
2021
Q4 | $69.6K | Sell |
30,797
-32,929
| -52% | -$74.4K | ﹤0.01% | 2460 |
|
|
2021
Q3 | $184K | Buy |
63,726
+31,245
| +96% | +$90K | ﹤0.01% | 2153 |
|
|
2021
Q2 | $123K | Sell |
32,481
-28,415
| -47% | -$108K | ﹤0.01% | 2388 |
|
|
2021
Q1 | $206K | Buy |
60,896
+28,800
| +90% | +$97.5K | ﹤0.01% | 2037 |
|
|
2020
Q4 | $89.9K | Buy |
32,096
+3,799
| +13% | +$10.6K | ﹤0.01% | 2232 |
|
|
2020
Q3 | $71K | Sell |
28,297
-29,880
| -51% | -$75K | ﹤0.01% | 2254 |
|
|
2020
Q2 | $790K | Buy |
58,177
+5,951
| +11% | +$80.8K | 0.01% | 1126 |
|
|
2020
Q1 | $396K | Buy |
52,226
+10,611
| +25% | +$80.4K | 0.01% | 1331 |
|
|
2019
Q4 | $263K | Sell |
41,615
-15,711
| -27% | -$99.3K | ﹤0.01% | 1828 |
|
|
2019
Q3 | $225K | Hold |
57,326
| – | – | ﹤0.01% | 1877 |
|
|
2019
Q2 | $277K | Buy |
57,326
+16,718
| +41% | +$80.9K | ﹤0.01% | 1836 |
|
|
2019
Q1 | $333K | Hold |
40,608
| – | – | ﹤0.01% | 1702 |
|
|
2018
Q4 | $225K | Buy |
40,608
+19,179
| +90% | +$106K | ﹤0.01% | 1841 |
|
|
2018
Q3 | $189K | Hold |
21,429
| – | – | ﹤0.01% | 2118 |
|
|
2018
Q2 | $214K | Hold |
21,429
| – | – | ﹤0.01% | 1893 |
|
|
2018
Q1 | $204K | Hold |
21,429
| – | – | ﹤0.01% | 1880 |
|
|
2017
Q4 | $319K | Buy |
+21,429
| New | +$319K | ﹤0.01% | 1674 |
|